BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Bartos A, Iancu I, Ciobanu L, Onaciu A, Moldovan C, Moldovan A, Moldovan RC, Tigu AB, Stiufiuc GF, Toma V, Iancu C, Al Hajjar N, Stiufiuc RI. Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes—A Preliminary Study. Nanomaterials 2022;12:2833. [DOI: 10.3390/nano12162833] [Reference Citation Analysis]
2 Graur F, Puia A, Mois EI, Moldovan S, Pusta A, Cristea C, Cavalu S, Puia C, Al Hajjar N. Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma. Materials 2022;15:3893. [DOI: 10.3390/ma15113893] [Reference Citation Analysis]
3 Crintea A, Dutu AG, Sovrea A, Constantin AM, Samasca G, Masalar AL, Ifju B, Linga E, Neamti L, Tranca RA, Fekete Z, Silaghi CN, Craciun AM. Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation. Nanomaterials (Basel) 2022;12:1376. [PMID: 35458084 DOI: 10.3390/nano12081376] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Milligan JJ, Saha S. A Nanoparticle's Journey to the Tumor: Strategies to Overcome First-Pass Metabolism and Their Limitations. Cancers (Basel) 2022;14:1741. [PMID: 35406513 DOI: 10.3390/cancers14071741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]